Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Therapeutic Drug Carrier Systems
Facteur d'impact: 2.9 Facteur d'impact sur 5 ans: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN Imprimer: 0743-4863
ISSN En ligne: 2162-660X

Volumes:
Volume 37, 2020 Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v25.i1.10
pages 1-61

Engineered Nanocarriers of Doxorubicin: A Current Update

Rajesh R. Patil
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, University of Mumbai, N.P.Marg, Mumbai 400 019, India
Swati A. Guhagarkar
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, University of Mumbai, N.P.Marg, Mumbai 400 019, India
Padma V. Devarajan
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, University of Mumbai, N.P.Marg, Mumbai 400 019, India

RÉSUMÉ

Doxorubicin remains the first line of treatment for various cancers ever since its discovery in 1971. Cardiotoxicity and nephrotoxicity associated with unformulated doxorubicin triggered the development of doxorubicin nanocarriers. Although the therapeutic profile of doxorubicin is appreciably improved by entrapping in nanocarriers, they are largely taken up by organs of the reticuloendothelial system. Engineered nanocarriers of doxorubicin refer to carriers modified to escape recognition by reticuloendothelial system and/or functionalized with target specific ligands for selective accumulation at the target site. The first developments in engineered nanocarriers were the stealth carriers. These effectively bypassed the reticuloendothelial system and enhanced the therapeutic profile of doxorubicin by enabling passive accumulation in tumors. Stealth nanocarriers of doxorubicin revealed significant decrease in cardiotoxicity and nephrotoxicity, which led to the approval of liposomal doxorubicin for clinical applications. Success of liposomal doxorubicin was soon dulled by the appearance of newer toxicities like palmar-plantar erythrodysesthesia commonly referred as hand foot syndrome. The search for the “magic bullet” of doxorubicin has further intensified and resulted in design of engineered nanocarriers with high specificity for cancer cells. This review charts the progress from nanocarriers to engineered nanocarriers of doxorubicin, and highlights the current status of engineered nanocarriers of doxorubicin in clinical trials.


Articles with similar content:

Development of Nanoscale Approaches for Ovarian Cancer Therapeutics and Diagnostics
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 3-4
Magnus Bergkvist, Sarah A. Engelberth, Nadine Hempel
Oral Colon-Specific Drug Delivery of Protein and Peptide Drugs
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.24, 2007, issue 1
Ruchita V. Kumar, Sanjay Singh, Vivek Ranjan Sinha, J. R. Bhinge, Asmita Singh, Rachana Kumria
Engineered PLGA Nanoparticles: An Emerging Delivery Tool in Cancer Therapeutics
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.28, 2011, issue 1
Amit K. Jain, Manasmita Das, Nitin K. Swarnakar, Sanyog Jain
Recent Advances in Nanoparticle-Based Targeted Drug-Delivery Systems Against Cancer and Role of Tumor Microenvironment
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.34, 2017, issue 4
Usman Ali Ashfaq, Muhammad Zubair Yousaf, Erum Yasmeen, Muhammad Riaz
Nanostructured Materials in Drug and Gene Delivery: A Review of the State of the Art
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.28, 2011, issue 2
Krutika Sawant, Kailash C. Petkar, Sandip S. Chavhan, Snezana Agatonovik-Kustrin